The 'must attend' late phase drug development conference
Late Phase Drug Development World will be one of the largest gatherings of pharmaceutical and biotech professionals in Europe
Late phase drug development is growing at around 20% annually, exceeding the growth rate of phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public safety concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
The content
Key issues to be addressed include:
*Strategic drivers
*Regulatory environment
*Registries and results databases
*Enabling technologies in late stage development
*Operational issues in late stage study management
*Best practice case studies
